Last reviewed · How we verify
Platform
At a glance
| Generic name | Platform |
|---|---|
| Also known as | Other injectable Disease Modification Treatments |
| Sponsor | Georgia State University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- WEB-BASED FILIAL THERAPY IN PEDIATRIC CANCER (NA)
- Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (PHASE2)
- Pragmatic Comparative Effectiveness Trial of Evidence-based, On-demand, Digital Behavioral Treatments for Chronic Pain (NA)
- A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis (PHASE2)
- Neuroimmune Responses to Exercise in Chronic Back Pain (NA)
- Rwanda Digital Dashboard Hybrid Type 3 Implementation Study (NA)
- Program for Fully Understanding Eating and Lifestyle Change (FUEL) (NA)
- IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Specimens (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Platform CI brief — competitive landscape report
- Platform updates RSS · CI watch RSS
- Georgia State University portfolio CI